07:53 AM EDT, 03/13/2024 (MT Newswires) -- Silence Therapeutics ( SLN ) reported a full-year 2023 loss Wednesday of 38.9 pence ($0.50) per share, narrowing from a loss of 41.9 pence a year earlier.

Two analysts polled by Capital IQ expected a loss of 38 pence.

Revenue for the year ended Dec. 31 was 25.4 million pounds, up from 17.5 million pounds a year earlier.

Analysts surveyed by Capital IQ expected 29 million pounds.

Shares of the company were up more than 7% in recent Wednesday premarket activity.

Price: 27.11, Change: +1.21, Percent Change: +4.67